WANGYue, CHENBin, LUWu-guang, CAIRui, XULiu-gang, HUANGDan, CAOPeng, SHENJian-ping, ZHOUQian. Protective Effect of Shikonin on Ach-CaCl2-Induced Atrial Fibrillation in Rats[J]. Journal of Nanjing University of traditional Chinese Medicine, 2020, 36(1): 78-82.
Citation: WANGYue, CHENBin, LUWu-guang, CAIRui, XULiu-gang, HUANGDan, CAOPeng, SHENJian-ping, ZHOUQian. Protective Effect of Shikonin on Ach-CaCl2-Induced Atrial Fibrillation in Rats[J]. Journal of Nanjing University of traditional Chinese Medicine, 2020, 36(1): 78-82.

Protective Effect of Shikonin on Ach-CaCl2-Induced Atrial Fibrillation in Rats

More Information
  • OBJECTIVE To evaluate the potential therapeutic effects and mechanism of shikonin on atrial fibrillation in vivo. METHODS Male Sprague-Dawley rats were injected with Ach-CaCl2 mixture to make atrial fibrillation model. They were divided into blank group, model group and shikonin group. 4 mg/(kg·d) Shikonin was given to the shikonin group by one-week gavage in advance, Then given Ach-CaCl2 mixture at the same time. The effects of shikonin on atrial fibrillation in rats were evaluated by electrocardiogram, color Doppler ultrasound, Masson staining, ELISA and Western blot. RESULTS Electrocardiogram showed that shikonin prolonged the induction time of atrial fibrillation; color ultrasonographic results showed that shikonin improved heart enlargement in rats with atrial fibrillation; shikonin inhibited serum inflammatory factors IL-6 and TNF-α in rats with atrial fibrillation; Western blot also showed that shikonin inhibited the expression of IL-6 and TNF-α in atrial tissue of atrial fibrillation rats. CONCLUSION Shikonin shows a protective effect on a rat model of atrial fibrillation.
  • [1]
    BORIANI G, DIEMBERGER I, MARTIGNANI C, et al. The epidemiological burden of atrial fibrillation: A challenge for clinicians and health care systems[J]. Eur Heart J, 2006, 27: 893-894.
    [2]
    BALL J, CARRINGTON MJ, MCMURRAY JJV, et al. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century[J]. Int J Cardiol, 2013, 167: 1807-1824.
    [3]
    徐永玄,杨萍,郭涛.房颤发生机制及治疗新进展[J]. 昆明医科大学学报,2019,40(5):135-138.
    [4]
    DA SILVA. Influence of inflammation and atherosclerosis in atrial fibrillation[J]. Curr Atherosclerosis Rep, 2017, 19(1): 2.
    [5]
    PAMUKCU B, LIP GYH. Dronedarone as a new treatment option for atrial fibrillation patients: Pharmacokinetics, pharmacodynamics and clinical practice[J]. Exp Opin Pharm, 2011, 12: 131-140.
    [6]
    GUO X, CHEN W, SUN H, et al. Kv1. 5 Inhibitors for treatment of atrial fibrillation: A tradeoff between selectivity and non-selectivity[J]. Curr Topics Med Chem, 2016, 16: 1843-1854.
    [7]
    ANDUJAR I, RIOS JL, GINER RM, et al. Pharmacological properties of shikonin-a review of literature since 2002[J]. Planta Med, 2013, 79: 1685-1697.
    [8]
    WANG S, ZHU Y, QIU R. Shikonin protects H9C2 cardiomyocytes against hypoxia/reoxygenation injury through activation of PI3K/Akt signaling pathway[J]. Biomed Pharm, 2018, 104: 712-717.
    [9]
    YANG J, WANG Z, CHEN DL. Shikonin ameliorates isoproterenol (ISO)-induced myocardial damage through suppressing fibrosis, inflammation, apoptosis and ER stress[J]. Biomed Pharm, 2017, 93: 1343-1357.
    [10]
    WANG XH, ZHANG JH, HU YN, et al. Effects of shikonin on apoptosis and oxidative stress of vascular endothelial cells induced by high glucose[J].Chin J Pathophysiol, 2018, 34: 1222-1227.
    [11]
    WOZAKOWSKA-KAPON B. Changes in left atrial size in patients with persistent atrial fibrillation: A prospective echocardiographic study with a 5-year follow-up period[J]. Int J Cardiol, 2005, 101: 47-52.
    [12]
    ZHANG YJ, MA N, SU F, et al. Increased TRPM6 expression in atrial fibrillation patients contribute to atrial fibrosis[J]. Exp Mol Pathol, 2015, 98: 486-490.
    [13]
    MAENG YS, LEE GH, CHOI SI, et al. Histone methylation levels correlate with TGFBIp and extracellular matrix gene expression in normal and granular corneal dystrophy type 2 corneal fibroblasts[J]. BMC Med Genom, 2015, 8: 74.
    [14]
    HARADA M, VAN WAGONER DR, NATTEL S. Role of inflammation in atrial fibrillation pathophysiology and management[J]. Circul J, 2015,79(3):495-502.
    [15]
    WU N, XU B, XIANG Y, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis[J]. Int J Cardiol, 2013, 169: 62-72.
    [16]
    CONWAY DSG, BUGGINS P, HUGHES E, et al. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation[J]. Am Heart J, 2004, 148: 462-466.
    [17]
    LI J, SOLUS J, CHEN Q, et al. Role of inflammation and oxidative stress in atrial fibrillation[J]. Heart Rhythm, 2010, 7: 438-444.
    [18]
    YANG Y, WANG J, YANG Q, et al. Shikonin inhibits the lipopolysaccharide-induced release of HMGB1 in RAW264.7 cells via IFN and NF-κB signaling pathways[J]. Int Immunopharmacol, 2014, 19: 81-87.
    [19]
    LU L, QIN A, HUANG H, et al. Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition[J]. Eur J Pharmacol, 2011, 658: 242-247.

Catalog

    Article Metrics

    Article views (785) PDF downloads (455) Cited by()
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return